AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical
device provider, today announced that AtriCure and certain selling
stockholders intend to offer shares of AtriCure common stock in a public
offering. AtriCure also expects to grant the underwriters a 30-day
option to purchase additional shares of its common stock to cover
over-allotments, if any. AtriCure plans to use the net proceeds from the
offering for general corporate purposes and working capital. AtriCure
will not receive any proceeds from the sale of common stock by the
selling stockholders.
Piper Jaffray & Co. is acting as the sole book-running manager.
Canaccord Genuity Inc., Leerink Partners LLC, Stifel and Barrington
Research Associates are acting as co-managers for the offering.
This offering will be made pursuant to a prospectus supplement to
AtriCure’s prospectus, dated January 15, 2014, filed as part of
AtriCure’s effective $150 million shelf registration statement. This
press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to these securities may be obtained by contacting
Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or
by email at prospectus@pjc.com.
About AtriCure, Inc.
AtriCure,
Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in
patients undergoing certain open concomitant procedures. AtriCure’s
AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely
implanted device for LAA management worldwide. The company believes
cardiothoracic surgeons are adopting its ablation and LAA management
devices for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 5.5 million people
worldwide.
Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements that address activities, events or
developments that AtriCure expects, believes or anticipates will or may
occur in the future, such as those relating to AtriCure’s expectations
with respect to the proposed public offering, earnings estimates
(including projections and guidance), other predictions of financial
performance, launches by AtriCure of new products and market acceptance
of AtriCure’s products. Forward-looking statements are based on
AtriCure’s experience and perception of current conditions, trends,
expected future developments and other factors it believes are
appropriate under the circumstances and are subject to numerous risks
and uncertainties, many of which are beyond AtriCure’s control. These
risks and uncertainties include the rate and degree of market acceptance
of AtriCure’s products, AtriCure’s ability to develop and market new and
enhanced products, the timing of and ability to obtain and maintain
regulatory clearances and approvals for its products, the timing of and
ability to obtain reimbursement of procedures utilizing AtriCure’s
products, AtriCure’s ability to consummate acquisitions or, if
consummated, to successfully integrate acquired businesses into
AtriCure’s operations, AtriCure’s ability to recognize the benefits of
acquisitions, including potential synergies and cost savings, failure of
an acquisition or acquired company to achieve its plans and objectives
generally, risk that proposed or consummated acquisitions may disrupt
operations or pose difficulties in employee retention or otherwise
affect financial or operating results, competition from existing and new
products and procedures or AtriCure’s ability to effectively react to
other risks and uncertainties described from time to time in AtriCure’s
SEC filings, such as fluctuation of quarterly financial results,
reliance on third party manufacturers and suppliers, litigation or other
proceedings, government regulation and stock price volatility. AtriCure
does not guarantee any forward-looking statement, and actual results may
differ materially from those projected. AtriCure undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise. A further list
and description of risks, uncertainties and other matters can be found
in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Copyright Business Wire 2014